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no one helped with their daily activities, 36% (n150) said their spouse helped
them, followed by child (9%, n37), friend (7%, n29), another relative (5%, n21),
parent (3%, n12), paid helper (3%, n12), visiting doctor/nurse (3%, n12). Among
those who sought caregiver help on daily basis (n195), two-thirds (64%) reported
being cared for by spouse, 42% said a friend, and 21% their child. When asked, who
helped (always/sometimes) in making health and medical care decision, 86% said
spouse, 51 % friend, and 46% child. Almost two-thirds (63%) indicated they had
right amount of caregiver support in making treatment choice for blood transfu-
sion, 61% reported they made an informed decision, whereas, 40% said they felt
pressured by others. Higher percentage (74%) of previously transfused individuals
agreed they have right amount of caregiver support inmaking a transfusion choice
compared to not transfused group (55%). CONCLUSIONS: Caregivers play an im-
portant role in helping individuals with their health and medical treatment deci-
sions. On a daily basis, primary caregivers are spouse, child, and friend. Individuals
have right amount of caregiver support when making treatment decisions.
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OBJECTIVES: Post-transplant expectations can be overwhelming. We assessed the
relationship between health literacy and unmet immunosuppressant (IS) drug in-
formation needs in kidney transplant recipients. We hypothesized that patients
with low health literacy have greater unmet IS drug information needs compared
to patients with optimal health literacy. METHODS: A cross-sectional survey was
mailed out to 300 kidney transplant patients recruited from a single urban trans-
plant center. Inclusion criteria were receiving post-transplant care at the center
and receiving the transplant 1 to 36 months before inception of the survey. A
validated scale measured functional, communicative and critical health literacy.
An unmet IS drug information need was defined as a person reporting some to a
significant problem and too little information on areas related to IS drug manage-
ment. A personwith 7 ormore unmet IS drug information needswas categorized as
having high unmet IS drug information needs. Logistic regression was used to
produce unadjusted and adjusted OR controlling for age, race, gender, and time
since transplant. RESULTS: A response rate of 50% was obtained. 61.3% of respon-
dents weremale and themean agewas 56.7 (/ 11.2) years. Cronbach’s alphas for
functional, communicative, and critical health literacy respectively were 0.87, 0.88
and 0.83. Patients with high functional health literacy (ORunadjusted: 0.23 [0.07,
0.82]; ORadjusted: 0.26 [0.06, 1.09]) and patients using the transplant staff as a
source of information about transplant medications (ORunadjusted: 0.43 [0.19,
0.94]; ORadjusted: 0.28 [0.10, 0.78]) were less likely to report high unmet IS drug
information needs. CONCLUSIONS: Patients with low functional health literacy
have high unmet IS drug information needs, which might affect the management
of their condition. It is important to assess patients’ health literacy, tailor commu-
nication and materials accordingly, and regularly reinforce IS issues in order to
meet their IS drug information needs.
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OBJECTIVES: Examine knowledge and information seeking behaviors towards
blood transfusions among individualswithChronic KidneyDisease (CKD) currently
not on dialysis. METHODS: An online survey was conducted from a nationally
representative patient panel in 1Q2011. Respondents were 18 years and diag-
nosed with CKD by a physician. Participants were asked about blood transfusion
history, information seeking behaviors, and knowledge about blood transfusion.
RESULTS: Of 416 respondents, 59% (n246) were female; 40% (n165) were 65
years. 35% (n144) had stage 4 and 58% (n240) stage 3 CKD. 54% (n226) were
anemic. 43% (n179) had received blood transfusion, whereas, 57% (n237) had no
transfusions. Top two sources of information were doctor (93.8%) and Internet
(80.5%). Among those previously transfused, 62% received right amount of infor-
mation, whereas, 34.6% received too little information, and 3.4% reported receiving
too much information. More than 80% of transfused indicated they knew the rea-
sons for and benefits of getting a blood transfusion. Less than two-thirds received
information about effects, risks, and time it would take, and only 26% knew the
costs. Over 60% said that it is extremely important to know right blood type, screen-
ing techniques and quality of blood, and risks of infections. Among previously
transfused, only half (50%) agreed that theymade an informed choice about receiv-
ing blood transfusions. Among the previously transfused, 77% agree that they
knew the benefits compared with 49% not transfused. Similarly among previously
transfused, 69% agreed that they knew the risks of blood transfusion compared to
51% with no transfusion history. CONCLUSIONS: Doctor’s office and Internet are
primary sources of information about blood transfusions. Gaps in knowledge exist
about benefits, risks, and costs of blood transfusions. A significant number feel that
they need more information about blood transfusion to make an informed choice.
Providers should consider adopting shared-decision making with their patients.
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OBJECTIVES: To evaluate the reliability and validity of the Thai translation of the
KDQOL-36 questionnaire, by focus on kidney disease specific dimensions. The
KDQOL-36 consists of SF-12, and 3 dimensions of kidney disease questionnaires
(the Symptom/ Problem list, Effects of Kidney Disease on Daily Life, and Burden of
Kidney disease).METHODS: Subjects were 167 hemodialysis patients and 62 peri-
toneal dialysis patients. Reliability was evaluated by using intraclass correlation
coefficients (ICCs) for test-retest reliability assessment with face to face inter-
view and Cronbach’s alpha for internal consistency. Construct validity was sup-
ported with convergent and discriminant validity using correlation between
SF-36, EQ-5D, VAS parameter and 3 dimensions of kidney disease question-
naires. Statistical analysis included descriptive statistics, Mann-Whitney U test,
and Cronbach’s alpha. RESULTS: Construct validity was satisfactory with the sig-
nificant difference less than 0.001 between two groups (lowest through 25 percen-
tile and higher than 75 percentile). The reliability coefficient for the Cronbach’s
alpha of the total scale of the KDQOL-36 were greater than 0.700 for all domains,
range from 0.706 to 0.827. ICCs ranging from 0.713 to 0.999. CONCLUSIONS: The
KDQOL-36 (Thai) is an appropriate tool for quality of life assessment and routine
care in dialysis patients.
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OBJECTIVES: Initial mass dose, renal disease recurrence, and immunosuppressant
nephrotoxicity affect long term graft function after kidney transplantation (KTx).
Chronic Kidney Disease (CKD) may impair work ability, job performance and in-
crease absenteeism. We sougt to evaluate the association of post-transplant CKD
with work ability and labor supply.METHODS:We contacted all patients at 2 Mid-
western KTx clinics. All consenting patients answered a questionnaire about socio-
demographic characters, working conditions, quality of life and work ability (Work
Ability Index, WAI). A second survey about labor supply was sent after 6 months.
We abstracted biochemistry results, treatments and comorbidities data from clin-
ical charts. We excluded patients with multiple or multi-organ transplant, and
laboratory evidence of an acute cardiac ischemic episode in the month prior to
assessment. At least one creatinine assessment in the 3 months screening period
and age between 18-65 yearswas required for inclusion.We assessed differences in
WAI and labor supply across CKD stages and Glomerular Filtration Rate (GFR) with
ordinary least square regression. RESULTS: We enrolled 577 patients in 2 mid-
westen clinic (response rate 82%). Of them 222met the inclusion/exclusion criteria.
The employment-to-population ratio was 63%. MeanWAI score was 38.85.9. CKD
severity was associated with WAI ( -0.24, p0.01). GFR was associated with WAI
after adjusting for possible confounders (0.06; p0.01). Ninty-three percent of
patients responded to the follow up survey. Of those employed at baseline 20% lost
their job and 25% of previously jobless had found one. Patients with severe CKD
worked 4.69 weeks less than subject with mild or moderate CKD (p0.03). GFR was
associated with labor supply during the 6-months follow up after adjusting for
possible confounders (0.07; p0.03) CONCLUSIONS: Severe CKD was associated
with a mild reduction in self-reported work ability and a strong reduction in labor
supply after kidney transplant.
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ERYTHROPOIETIN-STIMULATING AGENT (ESA) DOSE RECOVERY FOLLOWING
HOSPITALIZATION OF END STAGE RENAL DISEASE (ESRD) PATIENTS
Wang X1, Bond TC1, Rubin JL1, Yang A2
1DaVita Clinical Research, Minneapolis, MN, USA, 2Affymax, Palo Alto, CA, USA
OBJECTIVES: Hemodialysis (HD) patients are frequently hospitalized. Interruption
of normal dialysis and 3x/weekly ESA treatments, along with the cause of hospi-
talization, usually leads to declines in Hb and increased ESA utilization post-hos-
pitalization. To determine the impact of these changes on patient care and re-
source utilization, we assessed the time for HD patients to recover to pre-
hospitalization ESA dose levels. METHODS: In this retrospective time-to-event
analysis, we examined hospitalizations in adult (318 yrs old) HD patients from
January 1, 2009 to December 31, 2010. Hospitalizations preceded by  30 hospital-
free days were included. For patients experiencing increases in epoetin alfa (EPO)
dose in the 30 days after hospitalization versus the 30 days before, we determined
the number of days taken to achieve an EPO dose  the median per-session dose
before hospitalization. Patient timewas censored at re-hospitalization, transplant,
death, or discontinuation of dialysis. Pre-hospitalization EPO dose level was con-
sidered achieved at the first of 3 consecutive dialysis sessionswhere EPOwas given
at a dose  the median per-session dose in the 30 days pre-hospitalization.
RESULTS: A total of 88,627 hospitalization events were analyzed where EPO use
increased post-hospitalization; in 40% of these cases patients were censored
(mainly due to re-hospitalization) before reaching pre-hospitalization dose. Of
those where EPO dose recovered to pre-hospitalization levels, median time to
recovery was 49 days (mean 102 days). Restricting the analysis to patients with
pre-hospitalizationmedian doses not in the top or bottom 10% of the range gave
a median time to recovery of 51 days (mean 90 days). CONCLUSIONS: Hospital-
izations frequently require an increase in post-hospitalization EPO dose. In
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patients who recover to their pre-hospitalization EPO dose, post-hospitalization
ESA dose increases frequently persist for several months, possibly due to
missed ESA doses, lower Hb from hospital-related phlebotomy, or increased
inflammatory states post-hospitalization. Strategies to address the causes of
this should be evaluated.
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OBJECTIVES: US dialysis centers typically dose ESA at every session (3x/wk), en-
abling frequent titrations. A once-monthly ESA is currently under FDA consider-
ation. We recently demonstrated that more frequent Hb measurements and dose
titrations are associated with higher ESA utilization. We developed an economic
model to quantify the potential impact of switching from a 3x/wk ESA to one dosed
monthly, due to fewer titrations and fewer Hb measurements, not considering
other efficiencies (e.g., reduced administrations). METHODS: A cost-offset model
estimated total ESA utilization and cost for monthly vs. 3x/wk dosing. Utilization
inputs were derived from a retrospective study of prevalent ( 120 days), adult (
18 years old) hemodialysis patients (n78,730), dialyzing at a large dialysis organi-
zation between 01/01/09-12/31/10. Patients dosed 3x/wk experience 1.1 dose titra-
tions and 2.9 Hb measurements on average per patient-month. Each additional
monthly dose titration is associated with a 24.1% (95% CI: 21.5%-26.4%) increase in
total ESA dose. Based on once-monthly ESA vs. 3x/wk ESA data (Provenzano et al.,
ASN 2011), we projected patients on a once-monthly ESA would experience 0.8
titrations and 1 Hb measurement per month, and projected savings-based reduc-
tions ofmean titrations and tests. Price (derived from published sources), dose and
clinical equivalence were assumed across ESAs. Model outcomes include incre-
mental utilization and cost. RESULTS: The model predicts that switching patients
to monthly ESA could result in a 7.95% (95% CI; 7.10%–8.73%) reduction in per-
patient/month ESA utilization. This translates into savings of 5,322 (95% CI; 4,748–
5,839 U) ESA units/month/patient and $52.37 (95% CI; $46.72–$57.46) per-patient/
month. For an average facility (96 patients), we estimated ESA savings of 510,934
U/month and cost savings of $5,028/month. CONCLUSIONS: The model predicts
that increasing the interval between ESA dose adjustments, based upon the FDA
approval and administration of a once monthly ESA, could decrease ESA utiliza-
tion.
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OBJECTIVES: in themedical literature of co-occurrence of erectile dysfunction (ED)
and benign prostatic hyperplasia (BPH) in men range from 20 to 80% depending on
age, definition and severity of symptoms, and other patient characteristics studied.
This study identifies the co-occurrence of these conditions, using healthcare insur-
ance claims data, to provide payers with an estimate of these burdensome
conditions. METHODS: Patients with ED and/or BPH were identified by diagnostic
codes in the Thomson Reuters MarketScan® Database from January 1, 2007 to June
30, 2010. Patients in the samplewere categorized as having BPH, ED, or co-occurring
BPH and ED, and were examined by age group (younger men aged 40-64 and older
men 65 and above). RESULTS: Of 685,270 men who met eligibility criteria, 531,486
(77.6%) were younger men and 153,784 (22.4%) were older men. Overall, 416,228
(60.7%) were diagnosed with ED (mean age 52.5), 336,432 (49.1%) were diagnosed
with BPH (mean age 62.5), and 67,390 (9.8%) were diagnosed with both ED and BPH
(mean age 60.3) in the study period. Among youngermen, co-occurring ED and BPH
accounted for 9.1% inmenwith ED or BPH, 13.4% inmenwith ED and 21.9% inmen
with BPH. Among older men, co-occurring ED and BPH accounted for 12.5% in men
with ED or BPH, 34.3% inmenwith ED, and 16.5% inmenwith BPH. CONCLUSIONS:
In this analysis, co-occurring ED and BPH varied in men by age. In younger men,
co-occurring ED and BPH accounted for a greater percentage of those in the BPH
cohort, whereas, in oldermen, co-occurrence accounted for a greater percentage of
the ED cohort. This may be a reflection of coding in the claims data or may suggest
that men may not seek treatment for both conditions or prioritize conditions dif-
ferently as they age.
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OBJECTIVES: The CMS dialysis prospective payment system (PPS) uses patient
characteristics and comorbidities to calculate payments. The final list of multipli-
ers (case-mix adjusters; CMAs) was effective January 2011. We assessed patient
CMAs and their relationship to ESA and other resource utilization covered by the
PPS. METHODS: We conducted a retrospective analysis of adult (3 18 yrs old) he-
modialysis patients at a large dialysis organization from 1/1/2011-6/30/2011. Pa-
tient CMAs, ESA utilization, other bundled costs (IV medications and laboratory
tests), and number of sessions attendedwere assessed for associationwith the PPS
composite CMA. Differences in utilization were assessed in a stratified generalized
linear model analysis across all months. Outlier payments were added to the base-
payment for very high-cost patients. RESULTS: CMA values were strongly posi-
tively associated with per-session ESA utilization and per-session costs for other
bundle components (p 0.001). ESA dose was 1.24 times higher for patients in the
highest CMA category (1.5) relative to patients in the lowest CMA category (1.0).
Patients in the lowest CMA category had mean additional bundled costs of $8.76
and patients in the highest category had a cost of $11.99 dollars (p 0.001). CMA
valueswere inversely associatedwith number of attended sessions (11.75 attended
sessions in the lowest CMA group vs. 10.16 in the highest; p 0.001). ESA use
accounted for the highest proportion of total costs (0.598). CONCLUSIONS: This
study shows a strong association between CMAs and ESA utilization, additional
treatment costs, and missed sessions. Monthly average CMA values cluster tightly
around 1.0, indicatingmost patients donot qualify for CMS-definedCMAs; however
the strong association between CMA and resource utilization suggests an associa-
tion between the CMA level and patients’ treatment cost , therefore CMS should
implement processes to help dialysis providers gain access to the underlying CMA
conditions and diagnoses.
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OBJECTIVES: To provide a cost-effectiveness analysis of treatments for moderate
grade vesicoureteral reflux (VUR), an illness that accounts for an estimated $100
million in healthcare expenditures. Treatment options include antibiotics, nonsur-
gical endoscopic injection with dextranomer/hyaluronic acid, and surgical repair.
METHODS:A systematic review usingMEDLINE (search terms VUR, treatment, and
cost) for 2006- 2011. RESULTS: Dextranomer/hyaluronic acid injection is the more
cost-effective option compared to ureteral reimplantation when success rates for
dextranomer/hyaluronic acid injection are 58% per ureter for patients with unilat-
eral reflux and 75% per ureter for bilateral reflux. If increasing grades of reflux
require increasing volumes of dextranomer/hyaluronic acid, success rates of 73%
for unilateral reflux and 94% for bilateral reflux represent the break-point for cost-
effectiveness. In models where dextranomer/hyaluronic acid injection is repeated
if VUR does not resolve after initial injection, break-even success rates are 11% and
60% with unilateral reflux if success rates of initial injections were 70% and 55%,
respectively. Break-even success rates for second dextranomer/hyaluronic acid
injections are 29% and 77% per ureter with bilateral reflux, if success rates of initial
injections are 70% and 55%, respectively. Based on 2011 epidemiologic estimates of
5580 children who are candidates for VUR treatments, dextranomer/hyaluronic
acid injection endoscopic injections and clinical outcome success rates as reported
in recent studies, potential annual savings with dextranomer/hyaluronic acid
range from $1.5 million to $23 million. CONCLUSIONS: A nonsurgical approach is
potentially associated with beneficial outcomes and cost-effectiveness. Longer-
term studies are needed to refine the range of outcomes and downstream costs.
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OBJECTIVES: Testing the validity of ICD-9-CM codes to identify diabetic patients
with stage 3-5 chronic kidney disease (CKD) in claims data. METHODS: We con-
ducted a cross-sectional study using claims from a large commercial health plan.
Patients meeting the following criteria were included: 1) diagnosis of type 2 diabe-
tes; 2) 12 months of continuous health plan eligibility; and 3) 2 non-zero serum
creatinine lab values, at least 90 days apart, between January 1, 2004 and June 30,
2011.We identified 12 ICD-9-CM code groups potentially indicative of CKD stage 3-5
and validated them against a “gold standard”, defined as two laboratory claims, at
least 90 days apart, with an estimated glomerular filtration rate (eGFR) 60 mL/
min. eGFR was calculated using the CKD Epidemiology Collaboration equation and
the Modification of Diet and Renal Disease (MDRD) equation. We calculated sensi-
tivity, specificity, positive predictive value (PPV) and negative predictive value for
the selected codes. Exact binomial 95% confidence intervals (CIs) were derived, and
codes with a PPV whose lower CI bound was  80% were considered valid.
RESULTS: The study sample consisted of 383,970 patients. Approximately 16% of
the sample (N61,052) had stage 3-5 CKD based on the “gold standard”. ICD-9-CM
codes for chronic renal failure, stage 3-5 (585.3-5), had a PPV of 84.2% (CI: 83.7% -
85.7%). ICD-9-CM code 585.6, used for end-stage renal disease, had a PPV of 84.7%
(CI: 83.6% - 85.7%). ICD-9-CM code 285.21, used to describe anemia in CKD, had a
PPV of 85.4% (CI: 84.6% - 86.2%). For the remaining code groups, PPV ranged from
50% to 78%, with CIs of  2 percentage points. Similar results were obtained when
eGFR was calculated using the MDRD equation. CONCLUSIONS: This cross-sec-
tional validation study suggests that diabetic patients with stage 3-5 CKD can be
accurately identified in administrative claims data using selected ICD-9-CM codes.
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EQ-5D (UK AND THAI PREFERENCE WEIGHTS), SF-6D, AND VAS SCORES IN
DIALYSIS THAI PATIENTS
Thaweethamcharoen T, Vasuvattakul S, Noparatayaporn P
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OBJECTIVES: To evaluate the utility scores from EQ-5D (UK and Thai preference
weight), VAS, and SF-6D in dialysis patients and to compare the correlation be-
tween these scores and the disease specific scores using KDQOL-36. METHODS:
This study was a cross-sectional study. A Face-to-face interviews using EQ-5D and
KDQOL-36 were conducted from April to August 2011 with 160 hemodialysis pa-
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